Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | CFD | P00746 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17954206 | 0.87 | F2 (0.51) | CYP4F2CYP4A11NR4A2MRGPRX4MAOB | |
| SCHEMBL20215166 | 0.86 | KDR (0.52) | CYP4F2CYP4A11NR4A2MRGPRX4MAOB | |
| SCHEMBL17954331 | 0.83 | NR4A2 (0.48) | CYP4F2CYP4A11NR4A2MRGPRX4MAOB | |
| SCHEMBL18102828 | 0.83 | MRGPRX4 (0.62) | NR4A2MRGPRX4MAOBFFAR4BCHE | |
| SCHEMBL17954209 | 0.82 | TSHR (0.57) | CYP4F2CYP4A11NR4A2MRGPRX4MAOB | |
| SCHEMBL3683352 | 0.81 | MRGPRX4 (0.61) | CYP4F2CYP4A11NR4A2MRGPRX4MAOB | |
| SCHEMBL20799468 | 0.81 | TSHR (0.50) | CYP4F2CYP4A11NR4A2MRGPRX4ERN1 | |
| SCHEMBL379281 | 0.81 | MAOB (0.67) | CYP4F2CYP4A11NR4A2MRGPRX4MAOB | |
| SCHEMBL2137838 | 0.79 | MRGPRX4 (0.69) | CYP4F2CYP4A11NR4A2MRGPRX4MAOB | |
| SCHEMBL17954220 | 0.79 | RXRA (0.55) | MAOBTSHRSMN1; SMN2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988627-B2 | Formats for organic compounds for use in RNA interference | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20170137814-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-05-18 | — | — | US | disclosed |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160244756-A1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160215288-A1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137814-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | APOL1, APOB, LDLR | CYP4F2 1695/4885CYP4A11 2193/4885NR4A2 1373/4885 |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | RNGTT, NSUN2, NSUN3 | CYP4F2 4812/4885CYP4A11 4879/4885NR4A2 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.